ZYOMYX Awarded Grant from the CD4 Initiative at Imperial College London

--Development of a novel, inexpensive and simple test for disease status in HIV+ individuals--

HAYWARD, Calif., March 7, 2007 – Zyomyx, Inc., a leader in chip-based bioanalytical technologies, today announced it has been selected by Imperial College London’s CD4 Initiative to work on a new treatment management tool for HIV/AIDS patients in developing countries. The Company will co-develop a novel test for counting CD4+ T-lymphocytes in blood, a parameter that is a key input into the treatment algorithm for HIV/AIDS. The new test will be designed to be suitable for widespread use in resource-poor countries.

Zyomyx will receive milestone-dependent payments from Imperial College over the next four years for the development of this technology. Upon successful completion of the development program, the Company intends to manufacture the resulting product for global release. Imperial College’s CD4 Initiative is funded by the Bill & Melinda Gates Foundation.

“The absence of inexpensive, rapid, and robust CD4 counting tools jeopardizes global initiatives for fighting AIDS. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development and launch of an advanced but simple and inexpensive CD4 cell counting product that will meet the demanding specifications for use in developing countries” said Peter Wagner, Ph.D., President and CEO of Zyomyx. “We are grateful to the CD4 Initiative at Imperial College for inviting us to be part of this strong collaborative effort which will enable us to fully develop our initial CD4 technologies to product level.”

# # #

Contact:
Peter Wagner, Ph.D.
Chief Executive Officer
(510) 265-8001
pwagner@zyomyx.com

Zyomyx is a trademark of Zyomyx, Inc. All other trademarks are the property of their registered owners. All rights reserved.

> Back to Press Releases